Risk of gastric and non-cardia gastric adenocarcinoma in individuals receiving Helicobacter pylori eradication treatment in Sweden from 2005 to 2012 compared with the Swedish standard population, expressed as SIR with 95% CI
| Gastric adenocarcinoma | Non-cardia gastric adenocarcinoma | Cardia adenocarcinoma | ||||
| No of cases | SIR (95% CI) | No of cases | SIR (95% CI) | No of cases | SIR (95% CI) | |
| Total | 75 | 2.08 (1.63 to 2.60) | 69 | 2.64 (2.06 to 3.35) | 6 | 0.60 (0.22 to 1.30) |
| Follow-up time, years | ||||||
| 1–3 | 48 | 8.65 (6.37 to 11.46) | 43 | 10.74 (7.77 to 14.46) | 5 | 3.23 (1.04 to 7.54) |
| 3–5 | 21 | 2.02 (1.25 to 3.09) | 20 | 2.67 (1.63 to 4.13) | 1 | 0.35 (0.01 to 1.93) |
| 5–7.5 | 6 | 0.31 (0.11 to 0.67) | 6 | 0.43 (0.16 to 0.93) | 0 | NA |
| No of eradications | ||||||
| 1 | 61 | 1.88 (1.44 to 2.41) | 56 | 2.38 (1.80 to 3.10) | 5 | 0.56 (0.18 to 1.30) |
| 2 | 8 | 2.84 (1.22 to 5.59) | 7 | 3.45 (1.38 to 7.11) | 1 | 1.26 (0.02 to 7.02) |
| >2 | 6 | 7.44 (2.72 to 16.19) | 6 | 10.47 (3.82 to 22.78) | 0 | NA |
NA, not applicable; SIR, standardised incidence ratio.